Therefore, blocking ox-LDL-induced endothelial dysfunction mediated by the LOX-1/NOX-4/ NF-κB pathway may serve as a therapeutic strategy for the treatment of ASCVD. Here, NOX4 is linked to endothelial dysfunction.